Trial Profile
Clinical response of recurrence risk and the SGLT2 inhibitor of the ischemic heart disease
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Jul 2016
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Ischaemic heart disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Jul 2016 New trial record